Revive Therapeutics Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
6
- Stock Symbol
-
RVV
- Investments
-
5
Revive Therapeutics General Information
Description
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. The company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs.
Contact Information
Website
www.revivethera.comCorporate Office
- 82 Richmond Street East
- Toronto, Ontario M5C 1P1
- Canada
Corporate Office
- 82 Richmond Street East
- Toronto, Ontario M5C 1P1
- Canada
Revive Therapeutics Timeline
Revive Therapeutics Stock Performance
As of 20-Nov-2026, Revive Therapeutics’s current market cap is $3.1M with 445M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.1M | 445M | 225K |
Revive Therapeutics Financials Summary
As of 30-Jun-2026, Revive Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 9,238 | 9,238 | 6,132 | 2,334 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (741) | (741) | (7,879) | (4,177) |
| Net Income | (741) | (741) | (7,879) | (4,146) |
| Total Assets | 199 | 199 | 150 | 7,765 |
| Total Debt | 0 | 0 | 49 | 18 |
Revive Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Revive Therapeutics Comparisons
Industry
Financing
Details
Revive Therapeutics Competitors (7)
One of Revive Therapeutics’s 7 competitors is One World Cannabis, a Corporate Backed or Acquired company based in Israel.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| One World Cannabis | Corporate Backed or Acquired | Israel | ||||
| Repare Therapeutics | Formerly VC-backed | Saint-Laurent, Canada | ||||
| Appili Therapeutics | Formerly VC-backed | Halifax, Canada | ||||
| ConjuChem | Formerly VC-backed | Montreal, Canada | ||||
| Tetra Bio-Pharma | Corporation | Orleans, Canada |
Revive Therapeutics Patents
Revive Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025019927-A1 | Compositions, methods and uses of bucillamine in the treatment a victim exposed to a chemical warfare agent | Inactive | 27-Jul-2023 | ||
| US-20250352563-A1 | Method and use of psilocybin in the prevention and treatment of stroke | Inactive | 03-May-2022 | ||
| WO-2023212812-A1 | Method and use of psilocybin in the prevention and treatment of stroke | Inactive | 03-May-2022 | ||
| WO-2023184031-A1 | Method and use of bucillamine in the prevention and treatment of stroke | Inactive | 30-Mar-2022 | ||
| CA-3175679-A1 | Use of psilocybin in the treatment of neurological brain injury and migraines | Pending | 17-Apr-2020 | A61K31/675 |
Revive Therapeutics Signals
Revive Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Revive Therapeutics Investments & Acquisitions (5)
Revive Therapeutics’s most recent deal was a Corporate Asset Purchase with DiagnaMed (Intellectual Property For Neurological And Mental Health Disorders) for . The deal was made on 31-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| DiagnaMed (Intellectual Property For Neurological And Mental Health Disorders) | 31-Mar-2025 | Corporate Asset Purchase | Buildings and Property | ||
| PharmaTher (Psilocybin-Related Intellectual Property in Toronto, Canada) | 17-Feb-2021 | Corporate Asset Purchase | Buildings and Property | ||
| Psilocin Pharma | 04-Mar-2020 | Merger/Acquisition | Drug Discovery | ||
| Joint Venture (Revive Therapeutics / Herman Holdings) | 14-Nov-2019 | Joint Venture | Other Consumer Non-Durables | ||
| Mercury Capital II | 06-Jan-2014 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Revive Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Revive Therapeutics FAQs
-
When was Revive Therapeutics founded?
Revive Therapeutics was founded in 2012.
-
Where is Revive Therapeutics headquartered?
Revive Therapeutics is headquartered in Toronto, Canada.
-
What is the size of Revive Therapeutics?
Revive Therapeutics has 6 total employees.
-
What industry is Revive Therapeutics in?
Revive Therapeutics’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Revive Therapeutics a private or public company?
Revive Therapeutics is a Public company.
-
What is Revive Therapeutics’s stock symbol?
The ticker symbol for Revive Therapeutics is RVV.
-
What is the current market cap of Revive Therapeutics?
The current market capitalization of Revive Therapeutics is $3.1M.
-
Who are Revive Therapeutics’s competitors?
One World Cannabis, Repare Therapeutics, Appili Therapeutics, ConjuChem, and Tetra Bio-Pharma are some of the 7 competitors of Revive Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process